MENINGOKOK B ASISI

Meningokok-B'ye karsi gelistirilen, Bexero asisi; FDA onayini aldi.. Asi 10 yasindan buyuk cocuklara yapilacak.. 

Turkiyedeki, cocuk doktorlarina selam edilir. Simdiye kadar cocuklara yapilan uyduruk asilar hicbir ise yaramaz.. 

FDA Approves New Vaccine for Serogroup B Meningococcal Disease

By Kristin J. Kelley

Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH 

A second vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B has been approved by the FDA. Bexsero is approved for use in patients 10 to 25 years old. 

The agency approved the first serogroup B vaccine, Trumenba, 3 months ago. The older generation of vaccines cover four out of the five serotypes, and this newest pair covers the fifth.

Approval was based on trials of roughly 2600 adolescents and young adults. After vaccination, 62% to 88% of participants who received two doses of the vaccine had antibodies that killed three N. meningitidis serogroup B strains, compared with 0% to 23% prior to vaccination. 

The vaccine's safety was evaluated in separate studies comprising some 5000 patients in both the U.S. and other countries. The drug's effects were also monitored in some 15,000 college students who received it, prior to approval, during two outbreaks of meningococcal disease on college campuses. Common side effects included chills, diarrhea, fatigue, headache, injection site pain, and joint and muscle pain.

FDA news release (Free)

Yazar	Mesaj Konu Arama Konu Seçenekleri Yanıt Yaz Yeni Konu Oluştur Konuyu Yazdır Çeviri Konu
Dr.KadirTugcu Üye Profili Özel Mesaj Yolla Üyenin Mesajlarını Bul Arkadaş Listeme Ekle Uzman Kayıt Tarihi: 14 Ağu 2008 Durum: Aktif Değil Puanlar: 118067	Mesaj Seçenekleri Yanıt Yaz Alıntı Dr.KadirTugcu Bu mesaj kurallara aykırıysa buradan yöneticileri bilgilendirebilirsiniz. Teşekkürler(0) Alıntı Cevapla Konu: MENINGOKOK B ASISI Gönderim Zamanı: 26 Oca 2015 Saat 18:33
	Meningokok-B'ye karsi gelistirilen, Bexero asisi; FDA onayini aldi.. Asi 10 yasindan buyuk cocuklara yapilacak.. Turkiyedeki, cocuk doktorlarina selam edilir. Simdiye kadar cocuklara yapilan uyduruk asilar hicbir ise yaramaz.. FDA Approves New Vaccine for Serogroup B Meningococcal Disease By Kristin J. Kelley Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH A second vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B has been approved by the FDA. Bexsero is approved for use in patients 10 to 25 years old. The agency approved the first serogroup B vaccine, Trumenba, 3 months ago. The older generation of vaccines cover four out of the five serotypes, and this newest pair covers the fifth. Approval was based on trials of roughly 2600 adolescents and young adults. After vaccination, 62% to 88% of participants who received two doses of the vaccine had antibodies that killed three N. meningitidis serogroup B strains, compared with 0% to 23% prior to vaccination. The vaccine's safety was evaluated in separate studies comprising some 5000 patients in both the U.S. and other countries. The drug's effects were also monitored in some 15,000 college students who received it, prior to approval, during two outbreaks of meningococcal disease on college campuses. Common side effects included chills, diarrhea, fatigue, headache, injection site pain, and joint and muscle pain. FDA news release (Free)